Orion Health to deliver the world’s largest health information exchange in Saudi Arabia
AUCKLAND, New Zealand, March 24, 2022 /PRNewswire/ -- Orion Health, the world's number one health data platform provider, has set another global benchmark by agreeing to build the world's largest health information exchange (HIE) for the Kingdom of Saudi Arabia. The HIE will take data feeds from more than...
LIMACORPORATE INTRODUCES L.E.A.R.N. THE NEW PLATFORM FOR A UNIQUE MEDICAL EDUCATION EXPERIENCE
UDINE, Italy, March 24, 2022 /PRNewswire/ -- Limacorporate S.p.A., leading global orthopedic manufacturer, is proud to introduce L.E.A.R.N. - LimaCorporate's Education and Resource Network. L.E.A.R.N. is a new and unique medical education experience, platform and network supporting surgeons in restoring the eMotion of Motion for their patients. Surgeons will be able to set up their own customized pathway...
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies
SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2021 Annual Results. Business Highlights CT053: completed subject enrollment for pivotal Phase II trial in China, NDA submission...
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China
SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that CT041, an autologous CAR T-cell product candidate against the protein Claudin18.2 (CLDN18.2), has completed the first patient enrollment...
Smartee Raises US$ 80 Million in Series D Funding
BEIJING, March 23, 2022 /PRNewswire/ -- In March 2022, Smartee announced that it has closed its Series D funding round of US$ 80 million. This round of financing was led by Beijing Taikang Investment, followed by China Resources Consumer Fund II, Jiaxing Science City, Zhangjiagang Industrial Investment etc. and some existing shareholders. This round of financing will accelerate Smartee's...
Friso launches Good Poop-inspired bedding and family staycations on World Sleep Day
SINGAPORE, March 23, 2022 /PRNewswire/ -- On World Sleep Day, 18 March 2022, Friso revealed two new exciting ways that parents can talk to their little ones about the importance of good gut health. Fresh from the success of last year's junior sleepwear collaboration with homegrown kidswear label, Maison Q, the brands have come together once again to launch...
Clarivate Patient Centricity Report Underscores Need for Evolution from Selling Products to Building Relationships
LONDON, March 23, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, Walking the talk on patient centricity: An actionable and measurable model for life science companies, which provides analysis of personalized...
Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results
BEIJING, March 23, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Financial and Operational Highlights for the Fourth Quarter of and Fiscal Year 2021...
Telix Advances Development of Glioblastoma Therapy Program
MELBOURNE, Australia, March 23, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company's glioblastoma multiforme (GBM) therapy candidate TLX101 into the next stage of clinical development. TLX101 (4-L- iodo-phenylalanine, or 131I-IPA) is one of the Company's lead therapeutic clinical programs and has been granted orphan drug designation...
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax’ COVID-19 Vaccine in Adolescents ≥12 to <18 in India
First authorization of Novavax' COVID-19 vaccine in adolescent population received Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to <18 in India Authorization highlights immunogenicity and reassuring safety profile of Covovax in Phase 2/3 study of...
